| Indications for using IV immunoglobulin in children (DNB 1997/1)10 | Immunoglobulin | 1997 |
| Role of IVIG in pediatric practice (DNB 2000/1)15 | Immunoglobulin | 2000 |
| Indications for use of IV Immunoglobulin in Pediatric Practice (DNB 2006/1)10 | Immunoglobulin | 2006 |
| Briefly outline the uses for IV immunoglobulin (IVIG) in children (DNB 2007/2)10 | Immunoglobulin | 2007 |
| Enlist the common indications for the use of IVIG. Describe the mechanism of action, doses and its side effects (DNB 2010/1)3+3+2+2 | Immunoglobulin | 2010 |
| Describe in brief the diseases in which IVIG is used for treatment. Write the dosage, administration and side effects of IVIG (DNB 2010/2) 5+2+1+2 | Immunoglobulin | 2010 |
| Discuss indications and plausible mechanisms of action of intravenous immunoglobulin therapy in various pediatric disorders (DNB 2013/2)10 | Immunoglobulin | 2013 |
| Indication, mode of action and side effects of IVIG in Paediatric practice (DNB 2016/2)5, (DNB 2017/1)10, (DNB 2019/1)5 | Immunoglobulin | 2016 |
| Indications of IVIG therapy in pediatric practice (DNB 2020/2)5 | Immunoglobulin | 2020 |
| Intramuscular immunoglobulin (DNB 2023/2)5 | Immunoglobulin | 2023 |
| Clinical importance of Interferon (DNB 1998/2)10 | Interferon | 1998 |
| Pegylated interferons (DNB 2016/2)5 | Interferon | 2016 |
| Physiological basis and therapeutic basis of NO (DNB 1998/2)10 | Nitric Oxide | 1998 |
| Clinical use of NO (DNB 2003/2)15 | Nitric Oxide | 2003 |
| Inhaled Nitric Oxide Therapy - Therapeutics (DNB 2021/2)5 | Nitric Oxide | 2021 |
| Oral chelating agents (DNB 1994/2)15 | Chelating Agents | 1994 |
| Iron chelation therapy (DNB 2000/1)5, (DNB 2006/1)5 | Chelating Agents | 2000 |
| Iron chelating agents in Pediatric practice (DNB 2020/1)5 | Chelating Agents | 2020 |
| Describe various mechanisms for development of Drug Resistance by bacterial pathogens against antibiotics. What factors are known to enhance drug resistance? Enumerate Anti Staphylococcal agents (DNB 1993/1)25 | Antibiotics | 1993 |
| Cephalosporins (DNB 1994/1)15 | Antibiotics | 1994 |
| Enumerate pediatric conditions in which Erythromycin is the drug of choice (DNB 1997/1)10 | Antibiotics | 1997 |
| Mechanism of Drug resistance (DNB 1997/1)15 | Antibiotics | 1997 |
| Early detection of Chloramphenicol toxicity (DNB 2003/1)15 | Antibiotics | 2003 |
| Third generation cephalosporins (DNB 2003/1)15 | Antibiotics | 2003 |
| Aztreonam (DNB 2003/2)15 | Antibiotics | 2003 |
| Discuss the basis for development of antibiotic resistance. Outline the steps for prevention of antibiotic resistance (DNB 2004/2)5+5 | Antibiotics | 2004 |
| Management of infections by organisms producing extended spectrum beta lactamase (DNB 2006/1)10 | Antibiotics | 2006 |
| Principles of rational antibiotic therapy (DNB 2017/2)5 | Antibiotics | 2017 |
| Mechanisms of antibiotic resistance (DNB 2017/1)5 | Antibiotics | 2017 |
| Mechanisms of antibiotic resistance (DNB 2020/1)5 | Antibiotics | 2020 |
| Oral imipenems and antimicrobial resistance (DNB 2024/1)5 | Antibiotics | 2024 |
| Describe the antifungals available for systemic use in India with their dosage, route and duration of therapy for treatment of a) systemic candidiasis b) Invasive aspergillosis (DNB 2009/2)5+5 | Antifungals | 2009 |
| Antiviral drugs (DNB 1999/1)15 | Antiviral Drugs | 1999 |
| Direct acting antivirals for Hepatitis C in children (DNB 2022/2)5 | Antiviral Drugs | 2022 |
| Bronchodilators (DNB 1994/2)15 | Bronchodilators | 1994 |
| Recombinant Human Erythropoietin (DNB 1994/2)15 | Erythropoietin | 1994 |
| Therapeutic uses of Erythropoietin (DNB 2024/2)5 | Erythropoietin | 2024 |
| Mechanism of action, therapeutic dose, and adverse effects in children of low molecular weight heparins (DNB 2016/1)5 | Low Molecular Weight Heparins | 2016 |
| Mechanism of action, therapeutic dose, and adverse effects in children of magnesium sulphate (DNB 2016/1)5 | Magnesium Sulphate | 2016 |
| Enumerate newer drugs for treatment of Epilepsy with their uses (DNB 2002/1)15 | Antiepileptics | 2002 |
| Indications for the therapeutic use of newer anticonvulsants in childhood seizure states and their potential adverse effects (DNB 2007/1)10 | Antiepileptics | 2007 |
| Newer antiepileptic drugs (DNB 2013/1)5, (DNB 2015/1)4 (DNB 2015/2)5 | Antiepileptics | 2013 |
| Tabulate the mechanism of action, dosage, indications and side effects of the following a. Zonisamide b. Rufinamide c. Stiripentol d. Levetiracetam e. Lacosamide (DNB 2015/2)2x5 | Antiepileptics | 2015 |
| Newer antiepileptic drugs. Write the name, dosage and salient adverse effects in tabular form (DNB 2017/2)5 | Antiepileptics | 2017 |
| Current status of newer anti-epileptic drugs (DNB 2017/1)4 | Antiepileptics | 2017 |
| Mechanism of action of valproate as an anti-epileptic drug (DNB 2018/1)5 | Antiepileptics | 2018 |
| Mechanisms of supraventricular tachycardia and mode of action of adenosine in supraventricular tachycardia (DNB 2018/1)5 | Anti-arrhythmics | 2018 |
| Infliximab (DNB 2016/2) | Miscellaneous | 2016 |
| Aerosol therapy for respiratory disorders (DNB 2017/1) 5 | Miscellaneous | 2017 |
| Anti-cytokine drugs and their indication (DNB 2018/2)5 | Miscellaneous | 2018 |
| Haematopoetic growth factors (DNB 2018/2)5 | Miscellaneous | 2018 |
| Rituximab - mode of action, indication and adverse effects (DNB 2019/2)6 | Miscellaneous | 2019 |
| Role of sildenafil citrate in new born practise (DNB 2019/1)5 | Miscellaneous | 2019 |
| Drug surveillance (DNB 2020/2)5 | Miscellaneous | 2020 |
| Immunomodulators in pediatric patients (DNB 2020/2)5 | Miscellaneous | 2020 |
| Risk of acid suppression medications (DNB 2021/1)5 | Miscellaneous | 2021 |
| Pharmacokinetics of Acetaminophen (DNB 2021/2)5 | Miscellaneous | 2021 |
| Monoclonal antibody use in paediatric practice (DNB 2021/2)5 | Miscellaneous | 2021 |
| Rituximab (DNB 2022/1)5 | Miscellaneous | 2022 |
| Antihelminthic drugs (DNB 2022/1)5 | Miscellaneous | 2022 |
| Indications of Rituximab in pediatric diseases (DNB 2023/1)5 | Miscellaneous | 2023 |
| Enzyme replacement therapy (DNB 2024/2)5 | Enzyme Replacement | 2024 |